Fathom Therapeutics Scores $47 Million Series A

Fathom Therapeutics, formerly Atommap Corp., raised an oversubscribed $47 million Series A.

The round was led by Sutter Hill Ventures, with participation from Chemistry, Alexandria Venture Investments, and NY Ventures.

The funding will help Fathom advance its AI- and quantum chemistry-based drug discovery platform.

The deal underscores continued investor confidence in AI-driven biotech and new molecule design.